|
Investor Relations
Press Releases
Events & Presentations
Corporate Governance
Financial Information
Stock Information
Investor FAQs
Contact Us
Shareholder Tools
Email Alerts
Search Investor Relations
|
Press Releases
All Releases
 |
Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
May 19, 2008
|
9.5 KB |
|
| |
PRINCETON, N.J., May 19, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) has nominated PSI-7851 as a lead development candidate for the treatment of chronic hepatitis C virus (HCV). PSI-7851 is a proprietary nucleotide analogue polymerase inhibitor of HCV that is being advanced into Good Laboratory Practice (G...
|
|
Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
May 15, 2008
|
15.0 KB |
|
| |
PRINCETON, N.J., May 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, reported unaudited financial results for the second fiscal quarter ended March 31, 2008. Pharmasset r...
|
|
Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
May 14, 2008
|
11.4 KB |
|
| |
PRINCETON, N.J., May 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) has commenced dosing two additional cohorts of a 4-week Phase 1 study of R7128 in combination with Pegasys(R) (peginterferon alfa-2a) plus Copegus(R) (ribavirin) in both treatment-naive and treatment-experienced patients chronically-infec...
|
|
Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
May 13, 2008
|
7.3 KB |
|
| |
PRINCETON, N.J., May 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at the Rodman & Renshaw 5th Annual Global Healthcare Conference being held from May 19-20, 2008 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. Schaefer Price, Pharmasset's Chief Executive Officer, wil...
|
|
Pharmasset Selected to Join the NASDAQ Biotechnology Index
May 12, 2008
|
7.5 KB |
|
| |
PRINCETON, New Jersey, May 12, 2008 (PR Newswire Europe via COMTEX News Network) -- Index Changes Scheduled to Take Effect with the Market Open on Monday, May 19th - Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, is ...
|
|
Pharmasset Selected to Join the NASDAQ Biotechnology Index
May 12, 2008
|
7.6 KB |
|
| |
PRINCETON, N.J., May 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, is pleased to announce that it has been selected to join the NASDAQ Biotechnology Index effective wit...
|
|
Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Apr 25, 2008
|
14.7 KB |
|
| |
PRINCETON, N.J. and MILAN, Italy, April 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces the results of a 4-week Phase 1 clinical trial evaluating two oral dose levels of R7128 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in 50 treatment-naive patients chronically in...
|
|
Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
Apr 24, 2008
|
7.4 KB |
|
| |
PRINCETON, N.J., April 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at the Morgan Stanley Global Healthcare Unplugged Conference being held from April 30, 2008 to May 2, 2008 at the Ritz-Carlton Key Biscayne in Miami, Florida. Schaefer Price, Pharmasset's Chief Executive Officer,...
|
|
Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
Apr 24, 2008
|
13.7 KB |
|
| |
PRINCETON, N.J. and MILAN, Italy, April 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) will enroll two additional cohorts in the on- going Phase 1 study protocol to evaluate 4 weeks of combination therapy with R7128. R7128, a prodrug of PSI-6130, is a nucleoside analogue polymerase inhibitor of hepatitis ...
|
|
Pharmasset to Present at the Canaccord|Adams Hepatitis C Conference on Wednesday, April 9th
Apr 4, 2008
|
7.3 KB |
|
| |
PRINCETON, N.J., April 4, 2008, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at the Canaccord|Adams Hepatitis C Conference being held on April 9, 2008 at the St. Regis Hotel in New York, NY. Schaefer Price, Pharmasset's Chief Executive Officer, will provide an overview of the company...
|
|
Pharmasset Receives $10 Million of Working Capital
Mar 28, 2008
|
9.4 KB |
|
| |
PRINCETON, N.J., March 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) received a second loan of $10 million from Horizon Technology Finance under an existing working capital loan agreement that was entered into during September 2007. Pharmasset received the first loan of $10 million in October 2007 and, a...
|
|
Pharmasset Appoints Herbert J. Conrad as a Director
Mar 27, 2008
|
8.1 KB |
|
| |
PRINCETON, N.J., March 27, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS), a pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, is pleased to announce the appointment of Herbert J. Conrad as a member of the Board of Directors and the Nominati...
|
|
Pharmasset to Present at Cowen & Company's Health Care Conference on Tuesday, March 18th
Mar 10, 2008
|
7.3 KB |
|
| |
PRINCETON, N.J., March 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at Cowen & Company's 28th Annual Health Care Conference being held March 17-20, 2008 at Boston Marriott Copley Place in Boston, MA. Schaefer Price, Pharmasset's Chief Executive Officer, will provide an overview o...
|
|
Pharmasset to Present at Susquehanna's Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
Feb 27, 2008
|
7.5 KB |
|
| |
PRINCETON, N.J., Feb 27, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at Susquehanna Financial Group's Second Annual SIGnificant Investment Options in Healthcare Conference being held March 4-5, 2008 at the W Hotel in New York, NY. Schaefer Price, Pharmasset's Chief Executive Officer...
|
|
Pharmasset Reports First Fiscal Quarter 2008 Financial Results
Feb 14, 2008
|
15.1 KB |
|
| |
PRINCETON, N.J., Feb 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, reported unaudited financial results for the first fiscal quarter of 2008 ended December 31, 2007. Ph...
|
|
Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
Feb 6, 2008
|
9.9 KB |
|
| |
PRINCETON, N.J., Feb 06, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset (Nasdaq: VRUS) and Roche will present the R7128 monotherapy resistance profile at the EASL-AASLD-APASL-ALEH-IASL Conference on Hepatitis B & C Virus Resistance to Antiviral Therapies being held in Paris, France from February 14-16, 2008. The scientific abstra...
|
|
Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
Feb 1, 2008
|
7.5 KB |
|
| |
PRINCETON, N.J., Feb 01, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will be presenting at the BIO CEO & Investor Conference 2008 being held from February 11 - 13, 2008 at the Waldorf-Astoria Hotel in New York, NY. Schaefer Price, Pharmasset's Chief Executive Officer, will provide an overview of...
|
|
Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
Jan 7, 2008
|
13.9 KB |
|
| |
PRINCETON, N.J., Jan 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces the preliminary results of a 4-week Phase 1 clinical trial to evaluate two oral dose levels of R7128 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in 50 treatment-naive patients chronically infected...
|
|
Pharmasset to Present at the JPMorgan Healthcare Conference on Thursday, January 10th
Jan 2, 2008
|
6.8 KB |
|
| |
PRINCETON, N.J., Jan 02, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will be presenting at the 26th Annual JPMorgan Healthcare Conference being held from January 7-10, 2008 at the Westin St. Francis Hotel in San Francisco, CA. Schaefer Price, Pharmasset's President & Chief Executive Officer, wil...
|
|
Pharmasset Reports Fiscal Year End 2007 Financial Results
Dec 31, 2007
|
15.8 KB |
|
| |
PRINCETON, N.J., Dec 31, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, reported audited financial results for the fiscal year ended September 30, 2007. Pharmasset reported ...
|
|
|
= add release to Briefcase |
